Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.
暂无分享,去创建一个
M. McGuckin | S. Bowler | R. Lourie | Megan L. Martin | D. Serisier | A. Chen | Barbara Brain | Sally Biga | S. Schlebusch | P. Dash
[1] M. Chan-yeung,et al. Inhaled fluticasone in bronchiectasis: a 12 month study , 2005, Thorax.
[2] J. Soriano,et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. , 2007, Chest.
[3] A. Wells,et al. Azithromycin in bronchiectasis: when should it be used? , 2012, The Lancet.
[4] E. Gabazza,et al. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. , 2003, American journal of respiratory and critical care medicine.
[5] L. Gibson,et al. Storage and survival of bacteria by ultra‐freeze , 1986 .
[6] M. Greenstone,et al. Prolonged antibiotics for purulent bronchiectasis in children and adults. , 2007, The Cochrane database of systematic reviews.
[7] John Connett,et al. Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[8] J. Guggenbichler,et al. Influence of Macrolide Antibiotics on Promotion of Resistance in the Oral Flora of Children , 2001, Infection.
[9] K. Murray,et al. Relationship between area deprivation and the anticaries benefit of an oral health programme providing free fluoride toothpaste to young children. , 2004, Community dentistry and oral epidemiology.
[10] J. Maurer. Factors Associated With Lung Function Decline in Adult Patients With Stable Non-Cystic Fibrosis Bronchiectasis , 2009 .
[11] Wai Lam,et al. A pilot study of low-dose erythromycin in bronchiectasis. , 1999, The European respiratory journal.
[12] J. Nadel,et al. Neutrophil elastase induces mucin production by ligand-dependent epidermal growth factor receptor activation. , 2002, American journal of physiology. Lung cellular and molecular physiology.
[13] P. Cauchie,et al. A Phase I Determination of Azithromycin in Plasma during a 6-Week Period in Normal Volunteers after a Standard Dose of 500mg Once Daily for 3 Days , 1998, Clinical drug investigation.
[14] Susan R. Johnson,et al. Macrolide Resistance among Invasive Streptococcus Pneumoniae Isolates , 2022 .
[15] F. Accurso,et al. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. , 2001, American journal of respiratory and critical care medicine.
[16] M. Fine,et al. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. , 1992, The American journal of medicine.
[17] A. Hill,et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. , 2012, American journal of respiratory and critical care medicine.
[18] N. Karalus,et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial , 2012, The Lancet.
[19] A. O'donnell,et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. , 1998, Chest.
[20] N. Anthonisen,et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.
[21] B. Stricker,et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. , 2005, European heart journal.
[22] Megan L. Martin,et al. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. , 2011, Respiratory medicine.
[23] P. Jones,et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.
[24] D. Low,et al. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. , 2009, International journal of antimicrobial agents.
[25] D. Greenberg,et al. Community Prescribing and Resistant Streptococcus pneumoniae , 2005, Emerging infectious diseases.
[26] G. Tipoe,et al. Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro , 2003, European Respiratory Journal.
[27] Kenneth Meyer,et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. , 2000, American journal of respiratory and critical care medicine.
[28] H. Goossens,et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study , 2007, The Lancet.
[29] D. Hansell,et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival , 2009, European Respiratory Journal.
[30] S. Kudoh,et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. , 1998, American journal of respiratory and critical care medicine.
[31] D G Altman,et al. Statistics notes: Interaction 3: How to examine heterogeneity , 1996 .
[32] B. Rubin,et al. Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications , 2010, Clinical Microbiology Reviews.
[33] T. Seemungal,et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.
[34] M. Caniça,et al. Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14. , 2004, The Journal of antimicrobial chemotherapy.
[35] Sally J. Singh,et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ) , 2003, Thorax.
[36] P. King,et al. Microbiologic follow-up study in adult bronchiectasis. , 2007, Respiratory medicine.
[37] J. DiNicolantonio,et al. Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.